Yamada Mitsunori, Shimohata Mitsuteru, Sato Toshiya, Tsuji Shoji, Takahashi Hitoshi
Department of Pathology, Brain Research Institute, Niigata University, Japan.
Neuropathology. 2006 Aug;26(4):346-51. doi: 10.1111/j.1440-1789.2006.00670.x.
Polyglutamine diseases are hereditary neurodegenerative disorders that are caused by the expansion of a CAG repeat in the causative genes. They comprise at least nine disorders, including DRPLA, HD, and Machado-Joseph disease. Initially, the discovery of neuronal intranuclear inclusions (NIIs) in human brains and in a murine model of HD provided a plausible hypothesis that the expression of expanded polyglutamine stretches leads to NII formation, resulting in neuronal cell death in selective brain regions characteristic to each disease. Recent studies, however, suggest that nuclear dysfunction, especially transcriptional abnormalities caused by the diffuse intranuclear accumulation of mutant proteins, plays a pivotal role in the development and progression of clinical symptoms. Polyglutamine diseases have a similarity with neuronal storage disease, and this pathological process might become a target for the establishment of an effective therapy for these diseases.
聚谷氨酰胺疾病是遗传性神经退行性疾病,由致病基因中CAG重复序列的扩增引起。它们包括至少九种疾病,如齿状核红核苍白球路易体萎缩症(DRPLA)、亨廷顿舞蹈症(HD)和马查多-约瑟夫病。最初,在人类大脑和HD小鼠模型中发现神经元核内包涵体(NIIs),这提供了一个合理的假设,即扩展的聚谷氨酰胺片段的表达导致NII形成,从而在每种疾病特有的选择性脑区导致神经元细胞死亡。然而,最近的研究表明,核功能障碍,特别是由突变蛋白在核内弥漫性积累引起的转录异常,在临床症状的发生和发展中起关键作用。聚谷氨酰胺疾病与神经元贮积病有相似之处,这一病理过程可能成为建立这些疾病有效治疗方法的靶点。